News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision Therapeutics, Inc. to Present Clinical Data Showing Significant Association between ChemoFx® Results and Improved Outcomes in Recurrent Ovarian Cancer at the 2013 European Cancer Congress


6/20/2013 7:02:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Precision Therapeutics announced today that a recent clinical study supporting both the predictive and prognostic value of the ChemoFx® chemoresponse assay in recurrent ovarian cancer, has been accepted for poster presentation at the 2013 European Cancer Congress (ECCO-ESMO-ESTRO) to be held September 27 – October 1, 2013 in Amsterdam, Netherlands. The study, titled, Evaluation of a chemoresponse assay as both a prognostic and predictive marker in the treatment of persistent or recurrent ovarian cancer, will be presented as part of the “Diagnostics/Biomarkers” session of the biennial conference.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES